Business Wire

Lenovo Leaps Forward with Next-Generation ThinkAgile Composable Cloud Platform

Share

Lenovo Data Center Group (HKSE: 992) (ADR: LNVGY), one of the fastest growing hyperconverged infrastructure (HCI) vendors according to IDC, – with HCI revenue growing at almost twice the market growth rate in Q1 2018 (149.1% compared to 76.3%)—is further expanding its ThinkAgile portfolio to provide an innovative solution for customers who desire the agility of the public cloud and the security of a private cloud. To address this growing customer trend, Lenovo – together with Cloudistics – has developed the ThinkAgile CP Series composable cloud platform, a ‘cloud-in-a-box’ that offers all of the conveniences and ease-of-use of a public cloud environment secured behind the customer’s own data center firewall.

Lenovo ThinkAgile CP Series – with fully-integrated infrastructure, application marketplace and end-to-end automation of software-defined network, compute and storage – delivers a turnkey cloud experience that can be easily and centrally managed from anywhere through a software-as-a-service (SaaS) portal.

“As a global company that is unencumbered by legacy, Lenovo is uniquely positioned to not only listen to our customers and understand their pain points, but also develop revolutionary solutions that eliminate IT roadblocks and accelerate their business growth,” said Roderick Lappin, Senior Vice President, Worldwide Sales and Marketing of Lenovo Data Center Group. “The ThinkAgile CP Series is another example of how Lenovo is driving the industry forward by enabling customers to truly own their cloud experience in a secure, scalable and streamlined way.”

“Cloudistics’ private cloud computing platform cuts down application deployment cycles by 90%, which translates to faster time to revenue,” said Najaf Husain, Chief Executive Officer of Cloudistics. “We make private clouds as easy to use as the public cloud but with the control and performance enterprise customers want. Our partnership with Lenovo enables us to unleash a next-generation composable cloud platform to the market that is easy to implement, deploy, operate, maintain and support.”

The ThinkAgile CP Series features fully integrated high availability, backup, remote replication, usage metering, live help and support and multilayered, multitenant security. Customers can leverage a curated application marketplace (which they can extend with their own offerings) for rapid deployment and enjoy simple, plug-and-play scale-out of disaggregated units of compute and storage capacity. Lenovo ThinkAgile CP Series provides a premium experience for midmarket and enterprise customers seeking to take advantage of agile methodologies using a private cloud ecosystem. The platform is ideal for businesses or organizations that want the benefits of the public cloud, without compromising control, data security, application performance and service delivery.

“ICP had been an early adopter of the Cloudistics’ cloud platform as well as a Lenovo reseller. After hearing about these two companies coming together to deliver the Lenovo ThinkAgile CP Series, the entire ICP team jumped at the chance to position the new series to our valued customers,” said Sal Saglik, Director of Business Development, ICP Corp. “The ease of use, rapid deployment and scalability of ThinkAgile CP will allow us to deliver a cloud-like experience in a complete and secure solution without the costs and complexities of the public cloud.”

“The simplicity of the platform significantly changed our work output,” said Scott Whitehouse, IT Director at Integreon. “We are able to easily import applications, assign cloud computing resources and launch applications on-demand based on our organizational needs in a fraction of the time it used to take us.”

The Lenovo ThinkAgile CP Series is available through Lenovo and Cloudistics sales representatives and channel partners. Customer trials and proof-of-concept testing will begin in North America and Europe in August 2018 with further global rollout, including China, later this year. For more information, please visit http://www.lenovo.com/thinkagilecp

About Lenovo

Lenovo (HKSE: 992) (ADR: LNVGY) is a US$45 billion Fortune 500 company and a global technology leader in driving Intelligent Transformation through smart devices and infrastructure that create the best user experience. Lenovo manufactures one of the world’s widest portfolio of connected products, including smartphones (Motorola), tablets, PCs (ThinkPad, Yoga, Lenovo Legion) and workstations as well as AR/VR devices and smart home/office solutions. Lenovo’s data center solutions (ThinkSystem, ThinkAgile) are creating the capacity and computing power for the connections that are changing business and society. Lenovo works to inspire the different in everyone and build a smarter future where everyone thrives. Follow us on LinkedInFacebook, TwitterInstagramWeibo, or visit us at http://www.lenovo.com/

About Cloudistics

Cloudistics, a cloud software platform company, enables enterprises and service providers to deliver cloud services. Its software-defined technology natively converges network, storage, compute, virtualization, and management into a single platform to drive unprecedented simplicity in the data center. Customers can start with a base and scale to multi-site and multi-geo infrastructures with predictable economics and performance. With open and secure virtual networking, elastic all-flash storage, application orchestration and SaaS management, Cloudistics is the blueprint for application-optimized enterprise cloud infrastructures. Learn more at www.cloudistics.com or follow @cloudistics on Twitter.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Lenovo
David Hamilton (Global), dhamilton1@lenovo.com, +1 864 979 0024
Zeno Group (North America), LenovoWWDCG@zenogroup.com
Judith Schunke (EMEA), jschunke@lenovo.com, +44 7500 922556
or
Cloudistics
Declan Waters, declan@waterscomms.com, +1 408 510 0414

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 14:00:00 CEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

HiddenA line styled icon from Orion Icon Library.Eye